---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-030542"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2023-06-29T23:59:59+00:00"
generated_at: "2026-06-13T15:04:56.636245+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Candel Therapeutics stockholders elect three Class II directors and ratify KPMG as auditor at annual meeting

## Summary
- Elected Edward J. Benz Jr., Paul B. Manning, and Paul Peter Tak as Class II directors; each received over 10.7M votes for.
- Ratified KPMG as independent auditor for FY2023 with 15,388,012 for, 82,122 against, 1,081 abstain.
- Broker non-votes on director election totaled 4,502,642 shares.

## SEC filing metadata
- accession: 0000950170-23-030542
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2023-06-29T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017023030542/0000950170-23-030542-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017023030542/cadl-20230628.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-030542
- JSON: https://secwatch.observer/filing/0000950170-23-030542.json
- Plain text: https://secwatch.observer/filing/0000950170-23-030542.txt

## Key facts
- Shareholder Votes
  Candel Therapeutics, Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-28 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-28
  source text: The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, recommended for ratification in Proposal 2 at the Annual Meeting. The votes cast at the Annual Meeting were as follows: For Against Abstain 15,388,012 82,122 1,081
  evidence_url: https://www.sec.gov/Archives/edgar/data/1841387/000095017023030542/0000950170-23-030542-index.htm
- Shareholder Votes
  Candel Therapeutics, Inc. shareholders approved Election of three Class II directors at the 2023-06-28 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-28
  source text: The Company’s stockholders elected each of the Class II director nominees, Edward J. Benz Jr., M.D., Paul B. Manning, and Paul Peter Tak, M.D., Ph.D., FMedSci, recommended for election at the Annual Meeting in Proposal 1. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes Edward J. Benz Jr., M.D. 10,762,707 205,866 - 4,502,642 Paul B. Manning 10,903,287 65,286 - 4,502,642 Paul Peter Tak, M.D., Ph.D., FMedSci 10,930,887 37,686 - 4,502,642
  evidence_url: https://www.sec.gov/Archives/edgar/data/1841387/000095017023030542/0000950170-23-030542-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.